부산광역시내과

2026 대한조혈모세포이식학회 국제학술대회(ICBMT 2026) - 9월 18일(2일차)

Name: 2026 대한조혈모세포이식학회 국제학술대회(ICBMT 2026) - 9월 18일(2일차)
Start: 2026-09-18
End: 2026-09-18
Location: 벡스코

6.0점 일반 6.0

주최: 대한조혈모세포이식학회
일자: 2026-09-18
장소: 벡스코
수강료: 200,000원 구분별

수강료 구분별 상세보기

회원 150,000원, 비회원 200,000원, 기타 80,000원

원문 기준 · 정확한 등록비는 KMA 신청 페이지에서 확인하세요.

평점 구성

총 평점6.0점

필수평점0점

일반평점6.0점

연수평점은 3년 24점·연 8점 상한·필수 2점 요건이 있습니다. 이 행사 들으면 올해 상한까지 몇 점? →

KMA 등록 페이지에서 신청 → 평점 계산기

세부 일정 (73강)

08:30~09:00 Triple Targeting in Myelofibrosis with Momelotinib: An Integrated Therapeutic Approach via JAK1/2 and ACVR1 Inhibition Room C Seug Yun Yoon(Soonchunhyang University Seoul Hospital )
08:30~09:00 Immune Reconstitution and Infection Prevention After CAR T-cell and Bispecific Antibody Therapies: The Evolving Role of IVIG Room D Kwai Han Yoo(Seoul National University College of Medicine)
09:00~09:10 [구연발표]Development of FcRH5 as a therapeutic target in B-cell lymphoma Room A Jeonghwa Kim(Yonsei University College of Medicine)
09:10~09:20 [구연발표]Longitudinal Whole-Exome Sequencing Revealed Early Clonal Suppression and Delayed Resistance Evolution in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Ibrutinib Room A Ho Cheol Jang(Chonnam National University Hwasun Hospital)
09:20~09:30 [구연발표]Capturing the Landscape of Electronic Patient-Reported Outcomes During First-Line Lymphoma Therapy: A Multicenter Prospective Study Room A Kunye Kwak(Korea University College of Medicine)
09:30~09:40 [구연발표]Real-World Outcomes of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma (MEITL): a Taiwanese Multicenter Case Series Room A Chiayu Chen(China Medical University Hospital)
09:40~09:50 [구연발표]Overcoming Poor Prognosis in Post-CAR-T Relapse: Potential Utility of Bispecific Antibodies and Allogeneic Hematopoietic Stem Cell Transplantation as Effective Salvage Strategies Room A Gi June Min(Seoul St. Marys Hospital, College of Medicine)
09:50~10:00 [구연발표]Prior Bruton Tyrosine Kinase Inhibitor Exposure Is Associated with Inferior Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Mantle Cell Lymphoma Room A Tong-Yoon Kim(Yeouido St. Marys Hospital, College of Medicine)
09:00~09:10 [구연발표]Risk Stratification For Allogeneic Transplantation In Myelofibrosis: MTSS Versus AlloRisk And The Impact Of Driver Mutation Clearance Room B Yu-Sung Chang(National Taiwan University Hospital)
09:10~09:20 [구연발표]The Role of Pretransplant Cytoreductive Therapy in Patients with Chronic Myelomonocytic Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation Room B Jin Zhang(Peking University People)
09:20~09:30 [구연발표]Droplet digital PCR monitoring of JAK2V617F complements donor chimerism after allo-HSCT for myelofibrosis Room B So Yeon Park(Seoul St. Marys Hospital, College of Medicine, The Catholic University of Korea)
09:30~09:40 [구연발표]Linking Baseline Transcriptomics to Hematopoietic Recovery and Poor Graft Function After Allogeneic Transplantation for Myelofibrosis Room B Daehun Kwag(Seoul St. Marys Hospital, College of Medicine)
09:40~09:50 [구연발표]Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Myelofibrosis: a Chinese multicenter retrospective study Room B Yuqian Sun(Institute of Hematology, Peking University)
09:50~10:00 [구연발표]Integrative single-cell genotype-transcriptome analysis reveals mutant transcript and treatment-associated heterogeneity in JAK2 V617F-mutated myeloproliferative neoplasms Room B Ho Cheol Jang(Chonnam National University Hwasun Hospital)
09:00~09:10 [구연발표]Cost-Effectiveness of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Aged 65-69 Years Room C Jung Yeon Lee(Seoul St. Marys Hospital, College of Medicine)
09:10~09:20 [구연발표]One Thousand Autologous Stem Cell Transplants for Multiple Myeloma: Single center, retrospective analysis Room C Jun Ho Yi(Samsung Medical Center, Sungkyunkwan University School of Medicine)
09:20~09:30 [구연발표]Decoding the role of TANGO1 in myeloma proteostasis and therapeutic vulnerability Room C Ji Eun Lee(Yonsei University College of Medicine)
09:30~09:40 [구연발표]Long-term follow-up of busulfan plus cyclophosphamide and etoposide versus high-dose melphalan as conditioning in autologous stem cell transplantation for newly diagnosed multiple myeloma Room C Sungnam Lim(Inje University College of Medicine, Haeundae Paik Hospital)
09:40~09:50 [구연발표]Impact of Acute GVHD and Delayed Hematopoietic Recovery on the Incidence and Clinical Burden of Late Cytomegalovirus Reactivation and Disease After Letermovir Prophylaxis in CBT Room C Naoki Okada(Kurashiki Central Hospital)
09:50~10:00 [구연발표]Clinical and Basic Studies of Anti-CD25 Monoclonal Antibody for the Prevention of Acute Graft-versus-Host Disease Room C Yanfei Lu(The First Affiliated Hospital of Guangxi Medical University)
09:00~09:10 [구연발표]Letermovir for Cytomegalovirus Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia Patients: Results of the LETreal study Room D Yi Xia(Peking University People)
09:10~09:20 [구연발표]Real-World Analysis of Belumosudil in Chronic Graft-versus-Host Disease: Early Progression May Reflect Ruxolitinib Discontinuation-Associated Flare Room D Jae Ho Yoon(College of Medicine, The Catholic University of Korea)
09:20~09:30 [구연발표]Not All High-Risk Features Are Created Equal: Organ- and Subtype-Specific Determinants of Non-Relapse Mortality in TA-TMA Room D Seonghan Lee(Seoul St. Marys Hospital, College of Medicine, The Catholic University of Korea)
09:30~09:40 [구연발표]Targeting Steroid-Refractory Chronic GVHD with Reduced-Dose Rituximab Biosimilar (Truxima): A Phase 2 Prospective Study Room D Suhyeon Lee(St. Vincent Hospital, College of Medicine, The Catholic University of Korea)
09:40~09:50 [구연발표]Letermovir Prophylaxis real world data on Cytomegalovirus Reactivation in Paediatric Haematopoietic Stem Cell Transplantation Recipients: A Single-Centre experience Room D Krithika Krishnakumar(Apollo Cancer Center)
09:50~10:00 [구연발표]Hyperacute Fatal Transplant-Associated Thrombotic Microangiopathy with Catastrophic Central Nervous System Involvement after HLA-Matched Sibling Transplantation for Severe Aplastic Anemia Room D Moeko Hino(Chiba University Hospital)
10:00~10:10 휴식 ()
10:10~10:35 Insights into the Development of Cellular Therapy in China: Current Landscape and Future Directions Room A Meng Lv(National Clinical Research Center for Hematologic Disease)
10:35~11:00 Chimeric Antigen Receptor T-cell Therapy for Lymphoma in Korea: Current Status, Challenges, and Future Directions Room A Hyungwoo Cho(University of Ulsan College of Medicine)
11:00~11:25 Unlocking Access of CAR-T therapy in Taiwan: From Dual-Track Regulatory Transformation to National Insurance Breakthroughs Room A Bor-Sheng Ko(National Taiwan University Cancer Center)
11:25~11:50 Current Status and Challenges of CAR-T Cell Products in Japan: A Regulatory Perspective Room A Miki Nakamura(Pharmaceuticals and Medical Devices Agency)
10:10~10:40 Leukemic Stem Cells in AML: Mechanisms, Detection, and Therapeutic Targeting Room B Christopher Park(New York University Grossman School of Medicine)
10:40~11:10 Single-cell Genomics for Predicting and Dissecting Venetoclax Resistance in Monocytic AML Room B Seongseok Yun(Moffitt Cancer Center & Research Institute)
11:10~11:40 Information-driven Studeis on AML Room B Sunghyouk Park(College of Pharmacy, Seoul National University)
10:10~10:40 AI-Driven Prediction of Transplant Outcomes Room C Amin T. Turki(University Hospital Essen)
10:40~11:10 AI-Based Prediction of Early Relapse after CAR-T Therapy Room C Krishna V. Komanduri(University of California, San Francisco)
11:10~11:40 Clinical Relevance of BM fibrosis in MDS Using Digital Imaging Approaches Room C Junshik Hong(Seoul National University College of Medicine)
10:10~10:40 Autoimmune Cytopenia and Pure Red Cell Aplasia after HSCT Room D Kyung Taek Hong(Seoul National University College of Medicine)
10:40~11:10 Best Anti-fungal Prophylaxis and Treatment pre-/post-HSCT Room D Sung-Yeon Cho(The Catholic University of Korea)
11:10~11:40 Real World Management of CAR T Cell Toxicities-expert Opinion Room D Stephen A. Grupp(Childrens Hospital of Philadelphia)
11:50~12:00 휴식 ()
12:00~12:40 From Diagnosis to Transplant: Optimizing the Transplant Bridging Strategy in Secondary AML Room A Sang-A Kim(Seoul National University College of Medicine)
12:00~12:40 Unlocking the Clinical Value of Early CAR-T Therapy in Multiple Myeloma: Insights from the CARTITUDE-4 Experience Room C Youngil Koh(Seoul National University College of Medicine)
12:00~12:40 Donor Lymphocyte Infusion after Pediatric Haploidentical HSCT: Indications and Therapeutic Approach Room D Hee Young Ju(Sungkyunkwan University School of Medicine)
12:40~13:00 휴식 ()
13:00~13:30 Delegated Manufacturing: Bridging the Gap Between Commercial and Point-of-Care Models for Sustainable Advanced Cellular Therapy Programmes Room A William Hwang(National Cancer Centre Singapore and Singapore General Hospital)
13:30~14:00 Fine-tuning Signal Strength in CD5 CAR-NK Cells for Targeted T Cell Cancer Therapy Room A Tae-Don Kim(KRIBB)
14:00~14:30 Multispecific T Cell Engagers, γδ T Cells, and NK Cell–Based Immunotherapy Room A Kyung-Nam Koh(University of Ulsan College of Medicine)
13:00~13:30 Clinical Translation of Next-Generation Cellular Therapies for Acute Myeloid Leukemia: From Clinical Proof-of-Concept to Hematopoietic Stem Cell–Sparing Immunotherapy Room B Anthony Daniyan(Memorial Sloan Kettering Cancer Center)
13:30~14:00 Next-generation Switchable CAR-T Platform: Enhancing Precision and Efficacy in Solid Tumors Room B Kyungho Choi(Seoul National University College of Medicine)
14:00~14:30 Deep B Cell Depletion beyond Hematology: Immune Reset as a New Treatment Paradigm for Autoimmune Diseases Room B Ricardo Grieshaber-Bouyer(Erlangen-Nürnberg)
13:00~13:30 Ocular Diseases in Hematopoietic Stem Cell Transplantation Patients: Key Indicators for Immediate Recognition Room C Su-Kyung Jung(National Cancer Center)
13:30~14:30 From Diagnostics to Intervention: Managing Infections in Hematology Patients based on Imaging and Lab Results Room C Duk Hee Nho(College of Medicine, The Catholic University of Korea)
13:00~13:30 Recent Trends in Conditioning Regimens for Myeloid Malignancies Room D Ik-Chan Song(Chungnam National University College of Medicine)
13:30~14:00 PTCy as a Universal Platform for GVHD Prophylaxis: Integrating New Standards and Defining the Remaining Role of ATG Room D Mi Kwon(Gregorio Marañón University General Hospital)
14:00~14:30 Adult Cord Blood Transplantation Program for New Centers: A Practical Institutional Guide Room D Dong-Yeop Shin(Seoul National University College of Medicine)
14:30~14:40 휴식 ()
14:40~15:20 Evolution of Cellular Therapies in Management of Lymphoma Patients Room A Jakub Svoboda(University of Pennsylvania)
15:20~16:00 Management of Mixed Chimerism and Graft Failure in Non-malignant Diseases Room A Susan E. Prockop(Dana-Farber Cancer Institute)
16:00~16:10 휴식 ()
16:10~16:40 Poster Poster Zone 3F ()
16:40~16:50 휴식 ()
16:50~17:15 To Transplant Room A Mihee Kim(Chonnam National University Medical School)
17:15~17:40 Not to Transplant Room A Haerim Chung(Yonsei University College of Medicine)
17:40~18:05 Reduced Intensity Conditioning Room A Jin Kyung Suh(University of Ulsan College of Medicine)
18:05~18:30 Myeloablative Conditioning Room A Bo Ram Kim(Chonnam National University Hwasun Hospital)
16:50~17:15 EBV-Positive T/NK-Cell and B-Cell Lymphoproliferative Diseases: HSCT as Cure and as Complication Room C Dae-Ho Choi(Sungkyunkwan University School of Medicine)
17:15~17:40 Clinicopathological Spectrum of EBV-Positive T/NK-Cell Lymphoproliferative Diseases Room C Yoon Kyung Jeon(Seoul National University College of Medicine)
17:40~18:05 Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Outcomes from Japanese Nationwide Data Room C Ayumi Fujimoto(Kameda Medical Center)
18:05~18:30 A Japanese Registry-Based Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Hemophagocytic Lymphohistiocytosis Room C Haryoon Kim(Keio University)
16:50~17:20 Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in 2026 Room D Brenda Sandmaier(Fred Hutchinson Cancer Center)
17:20~17:50 Selection of Allogeneic Hematopoietic Progenitor Cell Donors Room D Brian C. Shaffer(Memorial Sloan Kettering Cancer Center)
17:50~18:20 Optimal Conditioning in Autologous HSCT Room D Jeong-Ok Lee(Seoul National University College of Medicine)